中国麻风皮肤病杂志 ›› 2021, Vol. 37 ›› Issue (6): 360-364.doi: 10.12144/zgmfskin202106360

• 论著 • 上一篇    下一篇

2%卡替洛尔滴眼液联合多磺酸粘多糖乳膏治疗婴儿血管瘤的疗效及安全性评价

王攀,郑源泉,卢静静,付桂莉   

  1. 华中科技大学同济医学院附属武汉儿童医院，武汉，430016
  • 出版日期:2021-06-15 发布日期:2021-05-27
  • 通讯作者: 付桂莉，E-mail: 157047064@qq.com

Assesment of efficacy and safety on 2% carteolol eye drops combined with mucopolysaccharide polysulfate cream in the treatment of infantile hemangioma

WANG Pan, ZHENG Yuanquan, LU Jingjing, FU Guili   

  1. Department of Dermatology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science &Technology, Wuhan 430016, China
  • Online:2021-06-15 Published:2021-05-27
  • Contact: FU Guili, E-mail: 157047064@qq.com

PDF (PC)

365

摘要： 目的：评价2%卡替洛尔滴眼液联合多磺酸粘多糖乳膏治疗中低风险婴儿血管瘤的临床疗效及安全性。方法：收集我院门诊中低风险婴儿浅表性血管瘤患儿，随机分为试验组和对照组，试验组给予2%卡替洛尔滴眼液联合多磺酸粘多糖乳膏外用治疗，对照组给予2%卡替洛尔滴眼液外用治疗，观察临床疗效及不良反应。结果：2016年12月至2020年11月共纳入218例患儿，其中试验组113例，对照组105例。试验组在治疗后1、3、6个月治疗后有效率分别为18.58%、55.75%、76.11%；对照组分别为18.10%、52.38%、72.38%。两组治疗后第1、3、6个月的有效率均无统计学差异（均P＞0.05）。不良反应为湿疹和溃疡，治疗后6个月试验组不良反应发生率1.77%，低于对照组9.52%（P＜0.05）。结论：多磺酸粘多糖乳膏不影响2%卡替洛尔滴眼液治疗中低风险婴儿浅表性血管瘤的临床疗效，但可减低湿疹和溃疡的发生率。

关键词: 血管瘤, 卡替洛尔, 多磺酸粘多糖乳膏

Abstract: Objective: To assessment the clinical efficacy and safety of 2% carteolol eye drops combined with mucopolysaccharide polysulfate cream in the treatment of low and medium risk infantile hemangioma. Methods: The infant with low and medium risk superficial infantile hemangioma in our hospital were recruited and randomly divided into experimental group and control group. The patients in experimental group were given topical 2% carteolol eye drops combined with mucopolysaccharide polysulfate cream. The patients in control group were given topical 2% carteolol eye drops. The clinical efficacy and adverse reactions in the two groups were assessed. Results: From December 2016 to November 2020, a total of 218 patients were recruited, including 113 in the experimental group and 105 in the control group. The effective rates in the experimental group at 1, 3, and 6 months of treatment were 18.58%, 55.75%, and 76.11%, which in the control group were 18.10%, 52.38%, 72.38%. There was no statistical difference of the effective rates between the two groups (Ps＞0.05). Adverse reactions included eczema and ulcers, and the incidence of adverse reactions at 6 months of treatment in the experimental group was 1.77%, which was lower than 9.52% in the control group, with a significant difference (P＜0.05). Conclusion: Mucopolysaccharide polysulfate cream does not affect the clinical efficacy of 2% carteolol eye drops in the treatment of low and medium risk superficial hemangioma, while it can reduce the incidence of eczema and ulcers. 

Key words: hemangioma, carteolol, mucopolysaccharide polysulfate cream